Villmed Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.50 M
as on 16-11-2024
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 44.90%
(FY 2023)
- Profit 13.69%
(FY 2023)
- Ebitda 8.27%
(FY 2023)
- Net Worth 22.82%
(FY 2023)
- Total Assets 125.51%
(FY 2023)
About Villmed Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Pushpendra Singh and Yogendra Singh serve as directors at the Company.
- CIN/LLPIN
U74999UR2018PTC008537
- Company No.
008537
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Mar 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Dehradun, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Villmed Laboratories Private Limited offer?
Villmed Laboratories Private Limited offers a wide range of products and services, including Organic and Inorganic Solvents, Alcohol Solvents, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines.
Who are the key members and board of directors at Villmed Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pushpendra Singh  | Director | 12-Mar-2018 | Current |
| Yogendra Singh | Additional Director | 25-Oct-2018 | Current |
Financial Performance of Villmed Laboratories.
Villmed Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 44.9% increase. The company also saw a substantial improvement in profitability, with a 13.69% increase in profit. The company's net worth Soared by an impressive increase of 22.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Villmed Laboratories?
In 2023, Villmed Laboratories had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rudralife Science Private LimitedActive 6 years 8 monthsPushpendra Singh and Yogendra Singh are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Villmed Laboratories?
Unlock and access historical data on people associated with Villmed Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Villmed Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Villmed Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
